Efficacy and safety of apomorphine pump infusion in Filipino patients insufficiently controlled on oral anti-Parkinson medications: an open-label, pilot study

Related Articles:

• The road ahead: 2022 January 20, 2022 # # # # The first post at the start of each year on the SoPD website tries to provide an overview of where things are in the search for ‘disease modifying’ therapies for Parkinson’s.  It is an exercise in managing expectations as well as discussing what research events are scheduled for the next year so that we can keep…
• The road ahead: 2021 January 25, 2021 # # # # At the start of each year, it is a useful practise to layout what is planned over the next 12 months. The events that are scheduled for the year to come, so that we can keep an eye out for them. Obviously, where 2021 will end actually is unpredictable, but an outline of what is scheduled…
• The road ahead: 2020 January 5, 2020 Here at the SoPD, we are primarily interested in disease modification for Parkinson’s. While there is a great deal of interesting research exploring the causes of the condition, novel symptomatic therapies, and other aspects of Parkinson’s, my focus is generally on the science seeking to slow, stop or reverse the condition. At the start of each year, it is a…
• Efficacy and safety of apomorphine pump infusion in Filipino patients insufficiently controlled on oral anti-Parkinson medications: an open-label, pilot study June 20, 2022 Int J Neurosci. 2022 Jun 20:1-10. doi: 10.1080/00207454.2022.2090352. Online ahead of print.ABSTRACTBackground: Apomorphine hydrochloride is used in the management of advanced Parkinson disease (PD), either as a rescue medication for off periods during levodopa therapy or as a maintenance pump medication. This is the first study to describe the effects of apomorphine in Filipino patients with PD.Objective: To evaluate the…
• Efficacy and safety of apomorphine pump infusion in Filipino patients insufficiently controlled on oral anti-Parkinson medications: an open-label, pilot study June 20, 2022 Int J Neurosci. 2022 Jun 20:1-10. doi: 10.1080/00207454.2022.2090352. Online ahead of print.ABSTRACTBackground: Apomorphine hydrochloride is used in the management of advanced Parkinson disease (PD), either as a rescue medication for off periods during levodopa therapy or as a maintenance pump medication. This is the first study to describe the effects of apomorphine in Filipino patients with PD.Objective: To evaluate the…
• Efficacy and safety of apomorphine pump infusion in Filipino patients insufficiently controlled on oral anti-Parkinson medications: an open-label, pilot study June 20, 2022 Int J Neurosci. 2022 Jun 20:1-10. doi: 10.1080/00207454.2022.2090352. Online ahead of print.ABSTRACTBackground: Apomorphine hydrochloride is used in the management of advanced Parkinson disease (PD), either as a rescue medication for off periods during levodopa therapy or as a maintenance pump medication. This is the first study to describe the effects of apomorphine in Filipino patients with PD.Objective: To evaluate the…
• Efficacy and safety of apomorphine pump infusion in Filipino patients insufficiently controlled on oral anti-Parkinson medications: an open-label, pilot study June 20, 2022 Int J Neurosci. 2022 Jun 20:1-10. doi: 10.1080/00207454.2022.2090352. Online ahead of print.ABSTRACTBackground: Apomorphine hydrochloride is used in the management of advanced Parkinson disease (PD), either as a rescue medication for off periods during levodopa therapy or as a maintenance pump medication. This is the first study to describe the effects of apomorphine in Filipino patients with PD.Objective: To evaluate the…
• 2019: Year in review December 31, 2019   In this end-of-year post, we review the Parkinson’s research that caught our attention at SoPD HQ in 2019. Month-by-month we will briefly discuss some of the major pieces of research/announcements that have defined the year and advanced our understanding of Parkinson’s. The list is based on nothing more than the author’s personal opinion – apologies to any researchers who…
• Shining a light on Parkinson’s November 7, 2019   NOTE: The information in today’s post should not be considered an endorsement of PhotoPharmics or the treatment they are proposing. The author of this blog has had no communication with the company. The information in this post is provided because the author has been asked by readers to discuss it. In October 2018, at the annual International Movement Disorders…
• Monthly Research Review – July 2021 July 31, 2021 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during July 2021. The post is divided into 10 parts based on the type of research: Top 5 pieces of Parkinson’s news Articles of general interest Basic biology…
• Monthly Research Review: January 2022 January 31, 2022 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during January 2022. The post is divided into 10 parts based on the type of research: Top 6 pieces of Parkinson’s news Articles of general interest Basic biology…
• Monthly research review – March 2021 March 31, 2021 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during March 2021. The post is divided into ten parts based on the type of research: Top 5 pieces of Parkinson’s news Articles of general interest Basic biology…
• Be one with Vitamin B1 April 13, 2022     # # # # BEFORE WE START: There are some topics that I am reluctant to address on this website, because there are folks within the community who have extremely vested interests in them. Thiamine (or Vitamin B1) is one of those topics. Some members of the Parkinson’s community have indicated to me that high doses of this…
• 2020: Year in Review January 1, 2021 # # # # In this end-of-year post, we review the Parkinson’s research that caught our attention at SoPD HQ in 2020. Month-by-month we will briefly discuss some of the major pieces of research/ announcements that have defined the year and advanced our understanding of Parkinson’s. The list is based on nothing more than the author’s personal opinion – apologies…
• Milestones in Parkinson’s Disease Research and Discovery April 11, 2017 “The real voyage of discovery consists not in seeking new landscapes, but in having new eyes.” Marcel Proust “The process of scientific discovery is, in effect, a continual flight from wonder.” Albert Einstein Preface:  Happy birthday to James Parkinson (neurologist, geologist, scientist, activist),  born April 11, 1755 and died December 21, 1824.  World Parkinson’s Day April 11, 2017. Introduction to…
• Monthly Research Review – February 2021 February 28, 2021 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during February 2021. The post is divided into eight parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news…
• Monthly Research Review – December 2020 December 31, 2020   At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during December 2020. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Conferences/lectures Other news…
• Isradipine: Posthoc analysis March 8, 2021 # # # # Last year the results of the large STEADY-PD study were published. The investigators behind the Phase III clinical trial reported that the experimental treatment being tested had no effect on the progression of Parkinson’s in recently diagnosed individuals. The treatment being evaluated was a calcium channel blocker called isradipine – it is used for treating high…
• The many variations of carbidopa/levodopa – the mainstay of Parkinson’s disease treatment March 9, 2021 How carbidopa/levodopa is used to treat Parkinson’s disease symptoms Loss of neurons in the brain that use dopamine to communicate is one of the hallmark features of Parkinson’s disease (PD), causing slowness, stiffness, tremor and balance problems. Replacing the brain’s dopamine is therefore one of the key treatment strategies to help improve the motor symptoms of PD. Dopamine itself does…
• Monthly Research Review – November 2020 November 30, 2020   At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during November 2020. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Conferences/lectures Other news…
• Monthly Research Review – January 2021 January 31, 2021 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during the previous 4 weeks. The post is divided into eight parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical…
• Monthly research review: February 2020 February 29, 2020   At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during February 2020. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Other news Review…